These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 21713078)
1. Epidemiology of therapy-related myeloid neoplasms after treatment for pediatric acute lymphoblastic leukemia in the nordic countries. Schmiegelow K Mediterr J Hematol Infect Dis; 2011; 3(1):e2011020. PubMed ID: 21713078 [TBL] [Abstract][Full Text] [Related]
2. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Schmiegelow K; Al-Modhwahi I; Andersen MK; Behrendtz M; Forestier E; Hasle H; Heyman M; Kristinsson J; Nersting J; Nygaard R; Svendsen AL; Vettenranta K; Weinshilboum R; Blood; 2009 Jun; 113(24):6077-84. PubMed ID: 19224761 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer. Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K; Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436 [TBL] [Abstract][Full Text] [Related]
4. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Bo J; Schrøder H; Kristinsson J; Madsen B; Szumlanski C; Weinshilboum R; Andersen JB; Schmiegelow K Cancer; 1999 Sep; 86(6):1080-6. PubMed ID: 10491537 [TBL] [Abstract][Full Text] [Related]
5. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Schmiegelow K; Forestier E; Kristinsson J; Söderhäll S; Vettenranta K; Weinshilboum R; Wesenberg F; Leukemia; 2009 Mar; 23(3):557-64. PubMed ID: 18987654 [TBL] [Abstract][Full Text] [Related]
6. Role of TPMT and ITPA variants in mercaptopurine disposition. Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964 [TBL] [Abstract][Full Text] [Related]
7. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952 [TBL] [Abstract][Full Text] [Related]
9. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426 [TBL] [Abstract][Full Text] [Related]
10. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites. Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235 [TBL] [Abstract][Full Text] [Related]
11. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia. Schmiegelow K; Bretton-Meyer U Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403 [TBL] [Abstract][Full Text] [Related]
12. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219 [TBL] [Abstract][Full Text] [Related]
13. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol. Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K; Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159 [TBL] [Abstract][Full Text] [Related]
14. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Lennard L; Welch JC; Lilleyman JS Br J Clin Pharmacol; 1997 Nov; 44(5):455-61. PubMed ID: 9384462 [TBL] [Abstract][Full Text] [Related]
15. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738 [TBL] [Abstract][Full Text] [Related]
16. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723 [TBL] [Abstract][Full Text] [Related]